Hostname: page-component-848d4c4894-ndmmz Total loading time: 0 Render date: 2024-05-15T07:34:08.263Z Has data issue: false hasContentIssue false
  • English
  • Français

Pharmaceutical Innovation: Law & the Public's Health

Published online by Cambridge University Press:  01 January 2021

Kevin Outterson
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Introduction
Information
Journal of Law, Medicine & Ethics , Volume 37 , Issue 2 , Summer 2009 , pp. 173 - 175
Copyright
Copyright © American Society of Law, Medicine and Ethics 2009

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

IMS Health Lowers 2009 Global Pharmaceutical Market Forecast to 2.5 – 3.5 Percent Growth, Press Release, April 22, 2009, available at <http://www.imshealth.com/portal/site/imshealth/menuitem.a46c6d4df3db4b3d88f611019418c22a/?vgnextoid=1e61fa8adbec0210VgnVCM100000ed152ca2RCRD&vgnextchannel=b5e57900b55a5110VgnVCM10000071812ca2RCRD&vgnextfmt=default> (last visited May 6, 2009).+(last+visited+May+6,+2009).>Google Scholar
See generally Outterson, K., “Pharmaceutical Arbitrage: Balancing Access and Innovation in International Prescription Drug Markets,” Yale Journal of Health Policy, Law & Ethics 5, no. 1 (2005): 193–291.Google Scholar
Hunt, P., “Human Rights Guidelines for Pharmaceutical Companies in Relation to Access to Medicines,” draft for consultation, September 19, 2007.Google Scholar
Bessen, J. and Meurer, M. J., Patent Failure: How Judges, Bureaucrats, and Lawyers Put Innovators at Risk (Princeton: Princeton University Press, 2008).Google Scholar
PhRMA, Pharmaceutical Industry Profile (2009).Google Scholar
Kesselheim, A. S. and Avorn, J., “Using Patent Data to Assess the Value of Pharmaceutical Innovation,” Journal of Law, Medicine & Ethics 37, no. 2 (2009): 176–183.CrossRefGoogle Scholar
Flynn, S., Hollis, A. and Palmedo, M., “An Economic Justification for Open Access to Essential Medicine Patents in Developing Countries,” Journal of Law, Medicine & Ethics 37, no. 2 (2009): 184–208.CrossRefGoogle Scholar
Bird, R. C., “Developing Nations and the Compulsory License: Maximizing Access to Essential Medicines While Minimizing Investment Side Effects,” Journal of Law, Medicine & Ethics 37, no. 2 (2009): 209–221.CrossRefGoogle Scholar
Lybecker, K. M. and Fowler, E., “Compulsory Licensing in Canada and Thailand: Comparing Regimes to Ensure Legitimate Use of the WTO Rules,” Journal of Law, Medicine & Ethics 37, no. 2 (2009): 222–239.CrossRefGoogle Scholar
Sonderholm, J., “Wild-Card Patent Extensions as a Means to Incentivize Research and Development of Antibiotics,” Journal of Law, Medicine & Ethics 37, no. 2 (2009): 240–246.CrossRefGoogle Scholar
Reichman, J. H., “Comment: A Trilogy of Views about Compulsory Licensing of Patented Pharmaceutical Inventions,” Journal of Law, Medicine & Ethics 37, no. 2 (2009): 247–263.CrossRefGoogle Scholar
Kapczynski, A., “Commentary: Innovation Policy for a New Era,” Journal of Law, Medicine & Ethics 37, no. 2 (2009): 264–668.CrossRefGoogle Scholar
Leonard, E. W., “Right to Experimental Treatment: FDA New Drug Approval, Constitutional Rights, and the Public's Health,” Journal of Law, Medicine & Ethics 37, no. 2 (2009): 269–279.CrossRefGoogle Scholar
Noah, B. A., “Just a Spoonful of Sugar: Drug Safety for Pediatric Populations,” Journal of Law, Medicine & Ethics 37, no. 2 (2009): 280–291.CrossRefGoogle Scholar
Crager, S. E. and Price, M., “Prizes and Parasites: Incentive Models for Addressing Chagas Disease,” Journal of Law, Medicine & Ethics 37, no. 2 (2009): 292–304.CrossRefGoogle Scholar
Patsner, B., “Riegel v. Medtronic, Inc.: Revisiting Pre-emption for Medical Devices,” Journal of Law, Medicine & Ethics 37, no. 2 (2009): 305–317.CrossRefGoogle Scholar